BEGIN:VCALENDAR VERSION:2.0 PRODID:-//https://www.takethedate.it///NONSGML kigkonsult.se iCalcreator 2.10.15// METHOD:PUBLISH BEGIN:VEVENT UID:20240328T162006CET-1215WkHem5@https://www.takethedate.it/ DTSTAMP:20240328T152006Z DESCRIPTION:We are delighted to invite you to the debate organised by \ ;PubAffairs Bruxelles \;which will be held on \;Wednesday \;th e \;22nd of November \;at \;19.00 \;at the premises of&nbs p\;Science14 Atrium\, \;rue de la Science\, 14-B\, Brussels. \;The event will consist of a debate about whether incentives \;in the biop harmaceutical industry are \;a hindrance or a benefit for Europe&rsquo \;s global competitiveness. \; \;Although speakers and event detai ls will be announced in the coming days\, we are publishing this event now to make sure you save the date.\nAbout the debate\nThe European Commissio n&rsquo\;s Communication on &lsquo\;Investing in a smart\, innovative and sustainable industry &ndash\; A renewed EU Industrial Policy Strategy&rsqu o\; \;was announced in the European Commission President Juncker&rsquo \;s September 2017 State of the Union address. The speech and the correspo nding new \;Industrial Policy Strategy \;place considerable emphas is on innovation. At the same time the European Commission\, as requested by EU member states in the EU Council Conclusions from June 2016\, is curr ently analysing if the \;IP incentives and rewards system for the biop harmaceutical industry is fit for purpose. This includes assessing the imp act of existing incentives on innovation\, availability\, accessibility an d health systems sustainability. The primary question being asked is if in centives are helping to bring innovative new treatments to patients in are as of unmet medical needs.\nThe sustainability of healthcare expenditures is an essential question for every EU member state. \;At the same time \, a change in the current IP incentives system would have an impact on Eu rope&rsquo\;s global competitiveness\, the innovative biopharma industry\, and the viability of European public-private partnerships in research. At stake are much needed high-skilled jobs and economic growth in Europe. So me commentators have argued that market exclusivity under the current IP r egime is hindering competition\, while others have pointed to the fact tha t a strong and predictable IP framework is needed to ensure investment int o complex and high-risk areas such as biopharma innovation.\nThe assessmen t of the possible impact of changing the existing IP incentives on Europe& rsquo\;s global competitiveness\, on patient&rsquo\;s access to innovative medicines\, and on future innovation in European biopharma is crucial\, e specially in light of the new EU industrial policy strategy. Can Europe le ad the world in life sciences\, with its citizens first to benefit from th e biologic and genomic revolution? Competitiveness of Europe and the bioph armaceutical industry: Are incentives a hindrance or a benefit?\nThis even t will be held under the \;Chatham House Rule. Participants are free t o use the information received but neither the identity nor the affiliatio n of the attendees may be revealed. For this reason\, unless explicitly au thorised by PubAffairs Bruxelles\, the filming and/or the recording of the event by any means are strictly forbidden.\nThe event will commence with a \;welcome drink \;at \;7h00 pm\, followed by \;a panel d ebate \;at \;7.30 pm. After the panel debate there will be an oppo rtunity for questions and discussions.
\nWe look forward to seeing you at& nbsp\;7h00 pm \;on the \;22nd of November \;at \;Science14 Atrium\, rue de la Science 14-B\, Brussels.\nAll our debates are followed by a drink in a convivial atmosphere. https://www.takethedate.it/Eventi/6 13-competitiveness-of-europe-and-the-biopharmaceutical-industry-are-incent ives-a-hindrance-or-a-benefit.html DTSTART:20171122T180000Z DTEND:20171122T200000Z LOCATION:Science14 Atrium (Bruxelles) SUMMARY:Competitiveness of Europe and the biopharmaceutical industry: Are i ncentives a hindrance or a benefit? URL:https://www.takethedate.it/Eventi/613-competitiveness-of-europe-and-the -biopharmaceutical-industry-are-incentives-a-hindrance-or-a-benefit.html END:VEVENT END:VCALENDAR